Stifel Nicolaus analyst Derek Archila reiterated a Hold rating on Galapagos (GLPG) today. The company’s shares closed last Monday at $148.25.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 10.9% and a 48.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Currently, the analyst consensus on Galapagos is a Hold with an average price target of $161.79, representing a 10.3% upside. In a report issued on October 5, RBC Capital also maintained a Hold rating on the stock with a $135.00 price target.
See today’s analyst top recommended stocks >>
Galapagos’ market cap is currently $9.69B and has a P/E ratio of 97.10. The company has a Price to Book ratio of 3.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Read More on GLPG:
